NASDAQ$APLT
Applied Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2020.
Applied Therapeutics reported financial results for the first quarter ended March 31, 2020, highlighting a period of tremendous growth and advancement across its clinical programs. The company is building out its commercial infrastructure and remains well capitalized.
- Company reported financial results for the first quarter ended March 31, 2020.
- The first quarter was a period of tremendous growth and advancement across clinical programs.
- Company began building out its commercial infrastructure in preparation for future launches.
- Company remains well capitalized as a result of the financing in January.
Headline financials
Revenue & EPS history
Applied Therapeutics · Revenue · Quarterly
$1M
Forward guidance
Applied Therapeutics looks forward to continuing its momentum throughout the rest of this year.
Tailwinds
- Launching pediatric study in Galactosemia.
- Continuing enrollment on the DbCM ARISE-HF study.
- Advancing additional new programs forward into the clinic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
-2.6%
Avg return
Earnings day
-9.9%
Avg return
5 days after
-14.9%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+24.0%
Q1 2025
Best reaction
-71.6%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -71.6% | -68.9% | -77.9% | |
| Q2 2025 | +5.6% | +9.1% | -5.6% | |
| Q1 2025 | +24.0% | -22.5% | -26.9% | |
| Q4 2024 | +0.1% | +4.3% | +1.5% | |
| Q3 2024 | +4.6% | +2.7% | -86.8% | |
| Q2 2024 | +5.7% | -4.4% | -6.4% | |
| Q1 2024 | -6.8% | -1.9% | -1.3% | |
| Q4 2023 | +7.3% | +2.6% | -6.2% | |
| Q3 2023 | -12.1% | -10.8% | +34.6% | |
| Q2 2023 | -3.2% | -14.1% | +1.3% | |
| Q1 2023 | -3.6% | -7.3% | -10.9% | |
| Q4 2022 | -5.6% | -7.9% | +6.3% | |
| Q3 2022 | -0.2% | — | — | |
| Q2 2022 | +3.0% | — | — | |
| Q1 2022 | -1.7% | — | — | |
| Q4 2021 | -9.1% | — | — | |
| Q3 2021 | +1.6% | — | — | |
| Q2 2021 | +3.6% | — | — | |
| Q1 2021 | -2.2% | — | — | |
| Q4 2020 | +3.3% | — | — | |
| Q3 2020 | +5.9% | — | — | |
| Q2 2020 | +13.8% | — | — | |
| Q1 2020 | +3.3% | — | — | |
| Q4 2019 | -27.7% | — | — | |
| Q3 2019 | -7.5% | — | — | |
| Q2 2019 | +7.0% | — | — | |
| Q1 2019 | -6.7% | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro